Company intelligence / Profile preview
Vector Vitale
North Miami Beach, Florida, United Statesvectorvitale.com ↗
- Ownership
- Private
- Employees
- ~24
- Development stage
- Other
01
Overview
Vector Vitale’s lead candidate KLS‑1 is currently in Phase 2 clinical trials for metastatic melanoma. The compound is also under investigation for prostate cancer, pancreatic cancer, CLL, and refractory glioblastoma. KLS‑1 consists of zinc aspartate highly enriched with the stable isotope zinc‑64. Early clinical work focuses on dose finding and safety; efficacy data have not been publicly disclosed.
- Therapeutic areas
- EndocrinologyOncologyNeurology
- Modalities
- Small moleculeProtein drugChemical drug
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
None publicly disclosed.
Beyond the preview
Go deeper on Vector Vitale.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vector Vitale.